Trial Profile
A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms DESTINY-Lung01
- Sponsors Daiichi Sankyo Inc
- 06 Apr 2024 According to Daiichi Sankyo Company Media Release, as part of Project Orbis, ENHERTU also is under regulatory review for the same indication by regulatory authorities in Australia, Brazil and Singapore.
- 06 Apr 2024 According to Daiichi Sankyo Company Media Release, ENHERTU has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on DESTINY-PanTumor02, DESTINY-Lung01 or DESTINY-CRC02, contingent upon verification and description of clinical benefit in a confirmatory trial.
- 29 Jan 2024 According to Daiichi Sankyo Company Media Release, sBLA is being reviewed under Real-Time Oncology Review (RTOR) programme and Project Orbis, two initiatives of FDA which are designed to bring safe and effective cancer treatments to patients as early as possible. The FDA has granted the application Priority Review in the US.